SDGR Stock Recent News
SDGR LATEST HEADLINES
Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR-Cas9.
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported that on June 11, 2024, the company granted (i) a non-statutory stock option and (ii) restricted stock units (RSUs).
Schrödinger is a hybrid biopharma company specializing in physics-based computational chemistry and traditional drug development. The company aims to utilize computational methods to create better drug candidates and improve strategic decision-making in clinical trials. Schrödinger has attracted substantial investment from strategic partnerships and has a diverse pipeline of drug candidates in clinical development.
Highlights from analysis from 24/7 Wall Street Analysts Eric Bleeker and Austin Smith can be found below.
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference.
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported that on May 16, 2024, the company granted restricted stock units (RSUs) to newly hired employees.
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.76 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.38 per share a year ago.
NEW YORK--(BUSINESS WIRE)--Schrödinger will report its first quarter 2024 financial results on Wednesday, May 1, 2024, after the financial markets close.
While the top- and bottom-line numbers for Schrodinger, Inc. (SDGR) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago.